Additional Information to the Items of Profit or Loss (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of Additional Information To Items Of Profit Or Loss [Abstract]

Schedule of information to the items of profit or loss

		Year ended December 31,
		2022			2021		2020
a.	Research and development expenses:
	Wages and related expenses	$	436		$	357	$	322
	Share-based payment		264			27		69
	Regulatory, professional and other expenses		750			934		119
	Research and preclinical studies		703			165		139
	Clinical studies		369			172		-
	Chemistry and formulations		281			335		-
			2,803			1,990		649
b.	General and administrative expenses:
	Wages and related expenses		437			256		237
	Share-based payment		633			16		22
	Professional and directors’ fees		2,499			2,417		1,283
	Business development expenses		161			5		58
	Regulatory expenses		162			165		98
	Office maintenance, rent and other expenses		224			135		182
	Wellution operating expenses		907			-		-
	Investor relations and business expenses		1,486			784		22
	General and administrative expenses:		6,509			3,778		1,902
c.	Other expenses:
	Impairment of company accounted for at equity		-			-		742
	Group’s share of losses of company accounted for at equity, net		109			-		-
			109			-		742
d.	Finance income:
	Net change in fair value of financial liabilities designated at fair value through profit or loss		(7,832	)		-		(630	)
			(7,832	)		-		(630	)
e.	Finance expenses:
	Issuance expenses related to warrants		1,204			6		835
	Exchange rate differences, net		4			3		12
	Losses from remeasurement of investment in financial assets		770			-		-
	Finance expense in respect of leases		15			4		7
	Finance expenses from interest and commissions		21			8		18
		$	2,014		$	21	$	872